| The first part :Artificial intelligence analysis of the clinical efficacy of Zhixue Quyu Mingmu tablet in the treatment of blood stasis and collateral injury,"fundus hemorrhage" of retinal vein occlusion due to yin deficiency and internal heat.Objective:to confirm and evaluate the efficacy of Zhixue Quyu Mingmu tablet in the treatment of retinal vein occlusion caused by blood stasis and internal heat due to yin deficiency.Methods:the patients with retinal vein occlusion caused by blood stasis and internal heat due to yin deficiency were randomly divided into two groups: Yikai group and traditional Chinese medicine group.Patients in both groups were treated with intravitreal injection of razumab.Razumab was injected continuously three times a month according to on-demand treatment(3+PRN).In this study,we only studied the therapeutic effect of the first three injections.The patients in the Yikai group were treated with pancreatic kininogenase enteric-coated tablets,and the patients in the traditional Chinese medicine combined group were treated with pancreatic kininogenase enteric-coated tablets combined with hemostasis and removing blood stasis Mingmu tablets for 12 weeks.Intraocular pressure,Best-corrected visual acuity Logarithm of the minimum angle of resolution{BCVA(Log MAR)},fundus bleeding area,central macular thickness(CMT),and Fovea avascular zone(FAZ),Choroidal blood flow area(CFA),Changes of blood vessel density in superficial retinal capillary layer(SCP)and deep retinal capillary layer(DCP)were observed before and after treatment,and observe the occurrence of adverse events and adverse reactions.Results:39 patients(39 eyes)with retinal vein occlusion caused by blood stasis and internal heat due to yin deficiency were randomly divided into two groups.There was no significant difference in age,sex and RVO classification between the two groups.1.There was no significant difference in BCVA(Log MAR),CMT,fundus bleeding area,FAZ,SCP,CFA and DCP between the two groups before treatment.2.BCVA(Log MAR)and CMT: During the follow-up for 12 weeks,the BCVA(Log MAR)and CMT of the two groups at each time point were significantly improved as compared with those before treatment,and the differences were statistically significant(P < 0.05),but there was no significant difference between the two groups(P > 0.05).3.Fundus bleeding area: during the follow-up for 12 weeks,the fundus bleeding area of the two groups at each time point was significantly lower than that before treatment(P < 0.05).The absorption of fundus hemorrhage in the traditional Chinese medicine combined group was better than that in the Yikai group at each time point,and the difference was statistically significant(P < 0.05).4.CFA: during the follow-up of 12 weeks,the CFA of each treatment time point in the traditional Chinese medicine combination group was significantly better than that before treatment,and the CFA in the Yikai group was significantly better than that before treatment at8 weeks and 12 weeks after treatment,and the difference was statistically significant(P < 0.05).The improvement of CFA in the traditional Chinese medicine combined group was better than that in the Yikai group at each treatment time point,and the difference was statistically significant(P < 0.05).5.DCP: during the 12-week follow-up,the DCP of the two groups showed a significant increase,and the DCP of each treatment time point in the traditional Chinese medicine combination group was significantly better than that before treatment,and the difference was statistically significant.8 weeks and 12 weeks after treatment,the DCP in the Yikai group was significantly better than that before treatment(P < 0.05).The improvement of DCP in the combination group was better than that in the Yikai group at 8 and 12 weeks after treatment,and the difference was statistically significant(P <0.05).6.FAZ area and SCP: there were no significant differences in FAZ area and SCP between the two groups before and after treatment(p>0.05),and there were no significant differences between the two groups(P >0.05).7.The intraocular pressure(IOP)of all patients was in the normal range(10-21 mm Hg)before treatment and at each time point of treatment.Conclusion:1.Leizumab combined with pancreatic kininogenase enteric-coated tablets,leizumab combined with pancreatic kininogenase enteric-coated tablets and hemostatic Quyu Mingmu tablets can eliminate macular edema,promote the absorption of fundus hemorrhage,improve patients’ visual acuity,improve choroidal blood flow and increase the density of deep retinal capillaries.2.Zhixue Quyu Mingmu tablet can better promote the absorption of fundus hemorrhage,improve choroidal blood flow and increase the capillary density of deep retina.3.There are no adverse reactions and adverse events in the process of taking Zhixue Quyu Mingmu tablet,so it is safe and reliable.The second part: Artificial intelligence to analyze the clinical efficacy of lecithin complex iodine capsule in the treatment of retinal vein occlusion.Objective: to analyze the clinical efficacy of lecithin complex iodine capsule combined with razumab in the treatment of retinal vein occlusion by artificial intelligence,in order to evaluate the clinical value of lecithin complex iodine capsule combined with razumab.Methods: patients with macular edema secondary to retinal vein occlusion((Macular edema secondary to Retinal vein occlusion,RVO-ME)were randomly divided into two groups: Yikai group and lecithin group.Patients in both groups were treated with intravitreal injection of razumab.Razumab was injected continuously three times a month according to on-demand treatment(3+PRN).In this study,we only studied the therapeutic effect of the first three injections.Patients in Yikai group were treated with pancreatic kininogenase enteric-coated tablets,and patients in lecithin combined with lecithin group were treated with pancreatic kininogenase enteric-coated tablets combined with lecithin complex iodine capsule for 12 weeks.The changes of intraocular pressure(IOP),BCVA(Log MAR),fundus bleeding area,CMT,FAZ,CFA,SCP and DCP blood vessel density before and after treatment were observed,and the adverse events and adverse reactions were observed.Results: 41 patients(40 eyes)with RVO-ME were randomly divided into two groups.There was no significant difference in age,sex and RVO classification between the two groups.1.There was no significant difference in BCVA(Log MAR),CMT,fundus bleeding area,FAZ,SCP,CFA and DCP between the two groups before treatment(p>0.05).2.BCVA(Log MAR)and CMT: During the follow-up for 12 weeks,the BCVA(Log MAR)and CMT of the two groups at each time point were significantly improved as compared with those before treatment,and the differences were statistically significant(P < 0.05),but there was no significant difference between the two groups(P > 0.05).3.Fundus bleeding area: during the follow-up for 12 weeks,the fundus bleeding area of the two groups at each time point was significantly lower than that before treatment(P < 0.05).The absorption of fundus hemorrhage in the lecithin combined group was better than that in the Yikai group(P < 0.05).4.CFA: at 8 and 12 weeks after treatment,CFA in both groups was significantly improved compared with that before treatment,and the difference was statistically significant(P < 0.05).The improvement of CFA in the lecithin combined group was better than that in the Yikai group at each treatment time point,and the difference was statistically significant(P < 0.05).5.DCP: 8 weeks and 12 weeks after treatment,the DCP of the two groups increased significantly,and the DCP of the two groups improved significantly compared with that before treatment,and the difference was statistically significant(P < 0.05).The improvement of DCP in the lecithin combined group was better than that in the Yikai group at 8 and 12 weeks after treatment,and the difference was statistically significant(P < 0.05).6.FAZ area and SCP: there were no significant differences in FAZ area and SCP between the two groups before and after treatment(p>0.05),and there were no significant differences between the two groups(P >0.05).7.The intraocular pressure(IOP)of all patients was in the normal range(10-21 mm Hg)before treatment and at each time point of treatment.Conclusion:1.Leizumab combined with pancreatic kininogenase enteric-coated tablets,leizumab combined with pancreatic kininogenase enteric-coated tablets and lecithin complex iodine capsule can eliminate macular edema,promote the absorption of fundus hemorrhage,improve patients’ visual acuity,improve choroidal blood flow and increase the density of deep retinal capillaries.2.Lecithin complex iodine capsule can better promote the absorption of fundus hemorrhage,improve choroidal blood flow and increase the density of deep retinal capillaries.3.There are no adverse reactions and adverse events in the process of taking lecithin complex iodine capsule,so it is safe and reliable. |
PDF Full Text Request